Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis

Abstract

BackgroundSo far, SARS-CoV-2 is the seventh coronavirus found to infect humans and cause disease with quite a strong infectivity. Patients diagnosed as severe or critical cases are prone to multiple organ dysfunction syndrome, acute respiratory distress syndrome and even death. Proinflammatory cytokine IL-6 has been reported to be associated with the severity of disease and mortality in patients with COVID-19.ObjectiveThis systematic review and meta-analysis were carried out to evaluate the association between IL-6 and severe disease and mortality in COVID-19 disease.MethodsA systematic literature search using China National Knowledge Infrastructure, Wanfang databases, China Science and Technology Journal Database, Chinese Biomedical Literature, Embase, PubMed and Cochrane Central Register of Controlled Trials was performed from inception until 16 January 2021.Results12 studies reported the value of IL-6 for predicting the severe disease in patients with COVID-19. The pooled area under the curve (AUC) was 0.85 (95% CI 0.821 to 0.931). 5 studies elaborated the predictive value of IL-6 on mortality. The pooled sensitivity, specificity and AUC were 0.15 (95% CI 0.13 to 0.17, I2=98.9%), 0.73 (95% CI 0.65 to 0.79, I2=91.8%) and 0.531 (95% CI 0.451 to 0.612), respectively. Meta-regression analysis showed that country, technique used, cut-off, sample, study design and detection time did not contribute to the heterogeneity of mortality.ConclusionIL-6 is an adequate predictor of severe disease in patients infected with the COVID-19. The finding of current study may guide clinicians and healthcare providers in identifying potentially severe or critical patients with COVID-19 at the initial stage of the disease. Moreover, we found that only monitoring IL-6 levels does not seem to predict mortality and was not associated with COVID-19’s mortality.PROSPERO registration numberCRD42021233649.

Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19

“…Others have reported a link between elevated IL6 and IL10 levels to fatality (Li et al, 2021) providing external validation of our data collected from leftover blood samples. However, these factors alone are not sufficient for prediction of outcome (Liu et al, 2021b). Our study also revealed CCL20 as a key correlate of fatal COVID-19.…”

Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population

“…Moreover, IL-6 is thought to be involved in COVID-19-associated coagulopathy through the generation of tissue factors and thrombin, stimulation of platelet activation, and induction of endothelial dysfunction [17] , [18] , [19] , [20] . Previous studies have demonstrated that serum levels of IL-6 are increased in patients with severe COVID-19, which is significantly correlated with adverse clinical consequences, including admission to the intensive care unit (ICU), ARDS, and death [21] , [22] , [23] , [24] .…”

Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2

“…Although the pathogenesis of COVID-19 severity remains unclear, numerous studies have shown an increase in the level of IL-6 and other proinflammatory cytokines in COVID-19 hospitalized patients and its association with the severity of the disease and mortality [ 2 – 4 ].…”